Goodwill
The latest quarterly goodwill is $51.60 Million with a quarter-over-quarter change of 0.00%. Goodwill is an intangible asset recorded when a company acquires another business for more than the fair value of its identifiable net assets.
PODD Goodwill
Reported quarterly goodwill; no daily interpolation.
Current Goodwill
$51.60M
$51.60 Million
Quarter-over-Quarter Change
0.00%
vs. $51.60M prior quarter
Historical Data
80
Quarters of data available
Quarterly Goodwill History
| Period | Goodwill | QoQ Change | % Change |
|---|---|---|---|
| Q1 2026 | $51.60M | +$0 | 0.00% |
| Q4 2025 | $51.60M | +$0 | 0.00% |
| Q3 2025 | $51.60M | $-100,000 | -0.19% |
| Q2 2025 | $51.70M | +$200,000 | +0.39% |
| Q1 2025 | $51.50M | +$0 | 0.00% |
| Q4 2024 | $51.50M | $-200,000 | -0.39% |
| Q3 2024 | $51.70M | +$0 | 0.00% |
| Q2 2024 | $51.70M | +$0 | 0.00% |
| Q1 2024 | $51.70M | +$0 | 0.00% |
| Q4 2023 | $51.70M | +$0 | 0.00% |
| Q3 2023 | $51.70M | +$0 | 0.00% |
| Q2 2023 | $51.70M | +$0 | 0.00% |
| Q1 2023 | $51.70M | +$0 | 0.00% |
| Q4 2022 | $51.70M | +$100,000 | +0.19% |
| Q3 2022 | $51.60M | $-200,000 | -0.39% |
| Q2 2022 | $51.80M | +$0 | 0.00% |
| Q1 2022 | $51.80M | +$12.00M | +30.15% |
| Q4 2021 | $39.80M | +$0 | 0.00% |
| Q3 2021 | $39.80M | $-100,000 | -0.25% |
| Q2 2021 | $39.90M | +$100,000 | +0.25% |
| Q1 2021 | $39.80M | +$0 | 0.00% |
| Q4 2020 | $39.80M | +$100,000 | +0.25% |
| Q3 2020 | $39.70M | +$100,000 | +0.25% |
| Q2 2020 | $39.60M | +$0 | 0.00% |
| Q1 2020 | $39.60M | $-200,000 | -0.50% |
| Q4 2019 | $39.80M | +$87,000 | +0.22% |
| Q3 2019 | $39.71M | $-26,000 | -0.07% |
| Q2 2019 | $39.74M | +$45,000 | +0.11% |
| Q1 2019 | $39.69M | +$48,000 | +0.12% |
| Q4 2018 | $39.65M | $-128,000 | -0.32% |
| Q3 2018 | $39.77M | +$43,000 | +0.11% |
| Q2 2018 | $39.73M | $-42,000 | -0.11% |
| Q1 2018 | $39.77M | $-67,000 | -0.17% |
| Q4 2017 | $39.84M | $-14,000 | -0.04% |
| Q3 2017 | $39.85M | +$95,000 | +0.24% |
| Q2 2017 | $39.76M | +$62,000 | +0.16% |
| Q1 2017 | $39.70M | +$20,000 | +0.05% |
| Q4 2016 | $39.68M | $-53,000 | -0.13% |
| Q3 2016 | $39.73M | $-33,000 | -0.08% |
| Q2 2016 | $39.76M | +$2,000 | +0.01% |
| Q1 2016 | $39.76M | +$154,000 | +0.39% |
| Q4 2015 | $39.61M | $-216,000 | -0.54% |
| Q3 2015 | $39.82M | +$2.29M | +6.09% |
| Q2 2015 | $37.54M | +$0 | 0.00% |
| Q1 2015 | $37.54M | +$0 | 0.00% |
| Q4 2014 | $37.54M | +$0 | 0.00% |
| Q3 2014 | $37.54M | +$0 | 0.00% |
| Q2 2014 | $37.54M | +$0 | 0.00% |
| Q1 2014 | $37.54M | +$0 | 0.00% |
| Q4 2013 | $37.54M | +$0 | 0.00% |
| Q3 2013 | $37.54M | +$0 | 0.00% |
| Q2 2013 | $37.54M | +$0 | 0.00% |
| Q1 2013 | $37.54M | +$0 | 0.00% |
| Q4 2012 | $37.54M | +$10.89M | +40.86% |
| Q3 2012 | $26.65M | +$0 | 0.00% |
| Q2 2012 | $26.65M | +$0 | 0.00% |
| Q1 2012 | $26.65M | +$0 | 0.00% |
| Q4 2011 | $26.65M | +$483,000 | +1.85% |
| Q3 2011 | $26.16M | $-563,000 | -2.11% |
| Q2 2011 | $26.73M | +$26.73M | — |
| Q1 2011 | $0 | +$0 | — |
| Q4 2010 | $0 | +$0 | — |
| Q3 2010 | $0 | +$0 | — |
| Q2 2010 | $0 | +$0 | — |
| Q1 2010 | $0 | +$0 | — |
| Q4 2009 | $0 | +$0 | — |
| Q3 2009 | $0 | +$0 | — |
| Q2 2009 | $0 | +$0 | — |
| Q1 2009 | $0 | +$0 | — |
| Q4 2008 | $0 | +$0 | — |
| Q3 2008 | $0 | +$0 | — |
| Q2 2008 | $0 | +$0 | — |
| Q1 2008 | $0 | +$0 | — |
| Q4 2007 | $0 | +$0 | — |
| Q3 2007 | $0 | +$0 | — |
| Q2 2007 | $0 | +$0 | — |
| Q1 2007 | $0 | +$0 | — |
| Q4 2006 | $0 | +$0 | — |
| Q3 2006 | $0 | +$0 | — |
| Q4 2005 | $0 | — | — |
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy